Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017.

Sheldon L Kaplan1, William J Barson2, Philana Ling Lin3

  • 1Department of Pediatrics, Pediatric Infectious Diseases Section, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas; skaplan@bcm.edu.

Pediatrics
|August 18, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections.

The Pediatric infectious disease journal·2026
Same author

Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Sex-specific trends in incident stroke: The Framingham Heart Study.

medRxiv : the preprint server for health sciences·2026
Same author

Pneumococcal Pneumonia in Hospitalized Children: 2017-2023.

Pediatrics·2026
Same author

Lifelong trajectories of modifiable vascular risk factors and relation to cerebral small vessel disease in the Framingham Heart Study.

medRxiv : the preprint server for health sciences·2026
Same author

Successful Bacteriophage Treatment of a Recalcitrant Intra-Abdominal Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa in a 2-Year-Old Child.

The Journal of pediatrics·2026
Same journal

Influenza Vaccine Effectiveness Against Pediatric Death in the United States: 2016-2025.

Pediatrics·2026
Same journal

Averting the Unthinkable: Immunization to Prevent Childhood Deaths From Influenza.

Pediatrics·2026
Same journal

Severe Postoperative Hypernatremia in an Adolescent Following Sleeve Gastrectomy.

Pediatrics·2026
Same journal

Barriers to Implementing SMART for Asthma in Pediatric Primary Care.

Pediatrics·2026
Same journal

Blood Lead Testing Among Children Enrolled in Medicaid.

Pediatrics·2026
Same journal

From Screening to Support: Crafting Social Needs Response Systems That Work for Families.

Pediatrics·2026
See all related articles
This summary is machine-generated.

Invasive pneumococcal disease (IPD) in children remains a concern, with PCV13 serotypes causing nearly a quarter of cases. Underlying conditions were more frequent in children with non-PCV13 serotype IPD.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Vaccinology

Background:

  • The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the US in 2010.
  • Invasive pneumococcal disease (IPD) remains a significant pediatric health concern.
  • Monitoring IPD trends post-vaccine introduction is crucial for public health.

Purpose of the Study:

  • To describe the epidemiology of IPD in children in the US between 2014 and 2017.
  • To identify the serotypes causing IPD in children after PCV13 licensure.
  • To investigate the clinical characteristics and immune status of children with IPD.

Main Methods:

  • A prospective study identified children with IPD at 8 US children's hospitals from 2014-2017.
  • Demographic, clinical, and vaccination data were collected.

Related Experiment Videos

  • Isolate serotypes were determined, and vaccine doses were counted if IPD occurred ≥2 weeks post-vaccination.

    • Main Results:

    • PCV13 serotypes accounted for 23.9% of IPD isolates.
    • Serotypes 3, 19A, and 19F were the most common PCV13 serotypes.
    • Underlying conditions were more prevalent in children with non-PCV13 serotype IPD (54.5%) compared to PCV13 serotype IPD (23.5%).
    • Immune evaluations in 28 children with PCV13 serotype IPD despite ≥2 PCV13 doses identified only one case of immunodeficiency.

    Conclusions:

    • PCV13 serotypes continue to cause a substantial proportion of pediatric IPD in the US.
    • Children with underlying conditions are more susceptible to non-PCV13 serotype IPD.
    • Immune evaluations in healthy children with PCV13 serotype IPD did not reveal significant immunodeficiency.